rx 821002 has been researched along with Parkinsonian Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schmidt, WJ; Srinivasan, J | 2 |
2 other study(ies) available for rx 821002 and Parkinsonian Disorders
| Article | Year |
|---|---|
Treatment with alpha2-adrenoceptor antagonist, 2-methoxy idazoxan, protects 6-hydroxydopamine-induced Parkinsonian symptoms in rats: neurochemical and behavioral evidence.
Topics: Adrenergic alpha-Antagonists; Analysis of Variance; Animals; Brain Chemistry; Catalepsy; Disease Models, Animal; Dopamine; Drug Interactions; Hydroxyindoleacetic Acid; Idazoxan; Male; Motor Activity; Norepinephrine; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Reaction Time; Serotonin; Statistics, Nonparametric | 2004 |
Serotonergic influence on the potentiation of D-amphetamine and apomorphine-induced rotational behavior by the alpha2-adrenoceptor antagonist 2-methoxy idazoxan in hemiparkinsonian rats.
Topics: Adrenergic Agents; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Dextroamphetamine; Drug Synergism; Idazoxan; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Serotonin; Sympatholytics | 2005 |